KW-136 With Sofosbuvir for Chinese Adults With Chronic Hepatitis C
Status:
Completed
Trial end date:
2018-03-07
Target enrollment:
Participant gender:
Summary
This study aimed to confirm efficacy and safety of KW-136, an investigational anti-hepatitis
C virus (HCV) drug, combined with sofosbuvir for treatment of naive and experienced adults
chronically infected with HCV. Three hundred and sixty (360) non-cirrhotic and cirrhotic
subjects were medicated with KW-136 60 mg daily and sofosbuvir 400 mg daily. The treatment
course lasted 12 successive weeks; thereafter all the study participants entered into a
12-week treatment-free follow-up period and an additional 12-week extension treatment-free
follow-up period.